scispace - formally typeset
M

Mónika Vastag

Publications -  52
Citations -  1035

Mónika Vastag is an academic researcher. The author has contributed to research in topics: Blood–brain barrier & Allosteric regulation. The author has an hindex of 16, co-authored 49 publications receiving 854 citations.

Papers
More filters
Journal ArticleDOI

Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models

TL;DR: While the complexity and predictive value of the BBB model is the highest, for the screening of NCEs to determine whether they are efflux substrates or not, the VB-Caco-2 and the MDCK-MDR1 models may provide a simple and inexpensive tool.
Journal ArticleDOI

Comparison of a Rat Primary Cell-Based Blood-Brain Barrier Model With Epithelial and Brain Endothelial Cell Lines: Gene Expression and Drug Transport

TL;DR: Among the tested culture models, the primary cell-based EPA model is suitable for the functional analysis of the BBB and the absence of gene expression of important BBB efflux and influx transporters BCRP, MRP6, MCT6, -8, PHT2, OATPs in one or both types of epithelial models suggests that Caco-2 or MDCK models are not suitable to test drug candidates which are substrates of these transporter.
Journal ArticleDOI

Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors.

TL;DR: Medicinal chemistry optimization of an impurity isolated during the scale-up synthesis of a pyridylsulfonamide type dopamine D(3)/D(2) compound led to a series of new piperazine derivatives having affinity to both dopamine D3 and D2 receptors.
Journal Article

Current in vitro and in silico models of blood-brain barrier penetration: a practical view.

TL;DR: This review gives a practical summary of in vitro and in silico approaches to evaluate BBB penetration, with models that provide sufficient predictivity, reliability and throughput to be favored by the pharmaceutical industry.